These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36722141)

  • 41. Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation.
    Christie RJ; Tiberghien AC; Du Q; Bezabeh B; Fleming R; Shannon A; Mao S; Breen S; Zhang J; Zhong H; Harper J; Wu H; Howard PW; Gao C
    Antibodies (Basel); 2017 Nov; 6(4):. PubMed ID: 31548535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hydrophobic interaction chromatography (HIC) method development and characterization of resolved drug-load variants in site-specifically conjugated pyrrolobenzodiazepine dimer-based antibody drug conjugates (PBD-ADCs).
    Janaratne T; Wang XC; Becker C; Zhao Y; Leanna R; Pritts W
    J Pharm Biomed Anal; 2020 Feb; 179():113027. PubMed ID: 31830625
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
    Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
    Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis, and evaluation of new noncross-linking pyrrolobenzodiazepine dimers with efficient DNA binding ability and potent antitumor activity.
    Kamal A; Ramesh G; Laxman N; Ramulu P; Srinivas O; Neelima K; Kondapi AK; Sreenu VB; Nagarajaram HA
    J Med Chem; 2002 Oct; 45(21):4679-88. PubMed ID: 12361394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
    Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
    Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data.
    Furqan F; Hamadani M
    Ther Adv Hematol; 2022; 13():20406207221087511. PubMed ID: 35340719
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR.
    Mao S; Chaerkady R; Yu W; D'Angelo G; Garcia A; Chen H; Barrett AM; Phipps S; Fleming R; Hess S; Koopmann JO; Dimasi N; Wilson S; Pugh K; Cook K; Masterson LA; Gao C; Wu H; Herbst R; Howard PW; Tice DA; Cobbold M; Harper J
    Mol Cancer Ther; 2021 Mar; 20(3):541-552. PubMed ID: 33653945
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs).
    Reid EE; Archer KE; Shizuka M; McShea MA; Maloney EK; Ab O; Lanieri L; Wilhelm A; Ponte JF; Yoder NC; Chari RVJ; Miller ML
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2455-2458. PubMed ID: 31350125
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Linker Immolation Determines Cell Killing Activity of Disulfide-Linked Pyrrolobenzodiazepine Antibody-Drug Conjugates.
    Zhang D; Pillow TH; Ma Y; Cruz-Chuh JD; Kozak KR; Sadowsky JD; Lewis Phillips GD; Guo J; Darwish M; Fan P; Chen J; He C; Wang T; Yao H; Xu Z; Chen J; Wai J; Pei Z; Hop CE; Khojasteh SC; Dragovich PS
    ACS Med Chem Lett; 2016 Nov; 7(11):988-993. PubMed ID: 27882196
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody-drug Conjugate Targeting AXL-expressing Cancers.
    Zammarchi F; Havenith KE; Chivers S; Hogg P; Bertelli F; Tyrer P; Janghra N; Reinert HW; Hartley JA; van Berkel PH
    Mol Cancer Ther; 2022 Apr; 21(4):582-593. PubMed ID: 35086955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: from Imaging to Therapy.
    Adhikari P; Li G; Go M; Mandikian D; Rafidi H; Ng C; Anifa S; Johnson K; Bao L; Hernandez Barry H; Rowntree R; Agard N; Wu C; Chou KJ; Zhang D; Kozak KR; Pillow TH; Lewis GD; Yu SF; Boswell CA; Sadowsky JD
    J Am Chem Soc; 2024 Jul; 146(28):19088-19100. PubMed ID: 38946086
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system.
    Wilson SC; Howard PW; Forrow SM; Hartley JA; Adams LJ; Jenkins TC; Kelland LR; Thurston DE
    J Med Chem; 1999 Oct; 42(20):4028-41. PubMed ID: 10514273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers.
    Rahman KM; James CH; Thurston DE
    Nucleic Acids Res; 2011 Jul; 39(13):5800-12. PubMed ID: 21427082
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody-Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization.
    Buongervino S; Lane MV; Garrigan E; Zhelev DV; Dimitrov DS; Bosse KR
    Mol Cancer Ther; 2021 Nov; 20(11):2228-2239. PubMed ID: 34465595
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma.
    Xu B; Li S; Kang B; Fan S; He Z; Zhou J
    Invest New Drugs; 2022 Dec; 40(6):1333-1341. PubMed ID: 36074313
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads.
    Kumar A; Kinneer K; Masterson L; Ezeadi E; Howard P; Wu H; Gao C; Dimasi N
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3617-3621. PubMed ID: 30389292
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
    Anderson MG; Zhang Q; Rodriguez LE; Hecquet CM; Donawho CK; Ansell PJ; Reilly EB
    BMC Cancer; 2021 Jun; 21(1):681. PubMed ID: 34107902
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
    Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
    Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Loncastuximab Tesirine: First Approval.
    Lee A
    Drugs; 2021 Jul; 81(10):1229-1233. PubMed ID: 34143407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.